Nuvalent, Inc.
NUVL
Ранг среди акций
#2106
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Цена акции
$123.96
Последняя синхронизация: 2026-07-21
Рыночная капитализация
$9.75B
Изменение (1 день)
0.00%
Изменение (1 год)
26.53%
Страна
US
Торговля Nuvalent, Inc. (NUVL)
Категория
Healthcare
EPS для Nuvalent, Inc. (NUVL)
EPS по состоянию на March 2026 TTM: $-6.06
Согласно последним финансовым отчетам и цене акций Nuvalent, Inc., текущий EPS компании (TTM) составляет $-6.06. В конце 2023 EPS компании составлял $-2.17, больше, чем показателю 2022 года, равному $-1.65.
История EPS компании Nuvalent, Inc. с 2019 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $-6.06 | 54.20% |
| 2024 | $-3.93 | 81.11% |
| 2023 | $-2.17 | 31.52% |
| 2022 | $-1.65 | -22.54% |
| 2021 | $-2.13 | 232.81% |
| 2020 | $-0.64 | 166.67% |
| 2019 | $-0.24 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | -385.81% |
US
|
|
| $-7.98 | 31.68% |
US
|
|
| $-5.29 | -12.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -557.76% |
NL
|
